Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Accured Expenses (2024 - 2025)

Xilio Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 1669.67% year-over-year to $3.3 million; the TTM value through Sep 2025 reached -$945000.0, changed N/A, while the annual FY2024 figure was -$496000.0, 383.43% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $3.3 million at Xilio Therapeutics, up from $879000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.3 million in Q3 2025 and bottomed at -$6.1 million in Q1 2025.